STOK
Stoke Therapeutics Inc

1,010
Mkt Cap
$1.96B
Volume
874,313.00
52W High
$38.69
52W Low
$5.35
PE Ratio
52.08
STOK Fundamentals
Price
$34.29
Prev Close
$34.37
Open
$34.26
50D MA
$31.69
Beta
1.31
Avg. Volume
758,015.20
EPS (Annual)
-$1.65
P/B
6.15
Rev/Employee
$285,585.94
$383.52
Loading...
Loading...
News
all
press releases
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 10.2% - Here's Why
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 10.2% - Here's Why...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
45,205 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Principal Financial Group Inc.
Principal Financial Group Inc. bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the third quarter, according to its most recent 13F filing with the...
MarketBeat·2d ago
News Placeholder
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·2d ago
News Placeholder
Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit
Stoke Therapeutics (NASDAQ:STOK) used its presentation at the Guggenheim Emerging Outlook Biotech Summit 2026 to highlight long-term clinical findings for its lead program in Dravet syndrome, outline...
MarketBeat·6d ago
News Placeholder
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine, today announced that the first patient...
Business Wire·10d ago
News Placeholder
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been given an average rating of "Moderate Buy" by the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports...
MarketBeat·11d ago
News Placeholder
Guggenheim Upgrades Stoke Therapeutics (NASDAQ:STOK) to "Strong-Buy"
Guggenheim upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a report on Thursday...
MarketBeat·14d ago
News Placeholder
Penserra Capital Management LLC Acquires New Position in Stoke Therapeutics, Inc. $STOK
Penserra Capital Management LLC bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC...
MarketBeat·15d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Trading 6.2% Higher - Here's What Happened
Stoke Therapeutics (NASDAQ:STOK) Trading Up 6.2% - Here's What Happened...
MarketBeat·22d ago
News Placeholder
Stoke Therapeutics, Inc. $STOK is Skorpios Trust's Largest Position
Skorpios Trust lowered its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 30.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The...
MarketBeat·1mo ago
<
1
2
...
>

Latest STOK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.